The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
ERBB receptors and cancer: the complexity of targeted inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“The recent identification of additional mutations in NSCLC patients whose tumours displayed drug-sensitive mutations and who initially responded to TKI treatment might explain some of the acquired resistance to EGFR inhibitor”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
The molecular biology of head and neck cancer
Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2982 · Cited by 2,524
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
“Intracellular pathways downstream of ErbB receptors ErbB receptors control key intracellular pathways that govern fundamental cellular processes including proliferation, cell migration, metabolism, and survival [1,21].”
BackgroundInfluentialSelf-citationCoactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Recent progress in tumor pH targeting nanotechnology
Lee, E. S., Gao, Z., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.003 · Cited by 866
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1970 · Cited by 789
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
Kalyankrishna, S., & Grandis, J. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8306 · Cited by 747
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Osteopontin: role in cell signaling and cancer progression
Rangaswami, H., Bulbule, A., & Kundu, G. C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.12.005 · Cited by 735
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Kumar, B., Cordell, K. G., Lee, J. S., Worden, F. P., Prince, M. E., Tran, H. H., Wolf, G. T., Urba, S. G., Chepeha, D. B., Teknos, T. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7662 · Cited by 612
Mitsudomi, T., & Yatabe, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00607.x · Cited by 606
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition
Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., & Brugge, J. S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505087 · Cited by 589
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Mitsudomi, T., & Yatabe, Y. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07448.x · Cited by 559
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Emerging roles of pseudokinases
Boudeau, J., Miranda-Saavedra, D., Barton, G. J., & Alessi, D. R. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.003 · Cited by 547
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
Bodenmiller, B., Zunder, E. R., Finck, R., Chen, T. J., Savig, E. S., Bruggner, R. V., Simonds, E. F., Bendall, S. C., Sachs, K., Krutzik, P. O., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2317 · Cited by 546
Gujrati, V., Kim, S., Kim, S.-H., Min, J. J., Choy, H. E., Kim, S. C., & Jon, S. (2014) · ACS Nano · doi:10.1021/nn405724x · Cited by 543
Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi, S., & Myers, J. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700104 · Cited by 516
Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. P., & Bellet, D. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml048 · Cited by 509
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Van Roey, K., Uyar, B., Weatheritt, R. J., Dinkel, H., Seiler, M., Budd, A., Gibson, T. J., & Davey, N. E. (2014) · Chemical Reviews · doi:10.1021/cr400585q · Cited by 502
Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495
Anti-cancer chalcones: Structural and molecular target perspectives
Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 495
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Pi, F., Binzel, D. W., Lee, T. J., Li, Z., Sun, M., Rychahou, P., Li, H., Haque, F., Wang, S., Croce, C. M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0012-z · Cited by 494
A module of negative feedback regulators defines growth factor signaling
Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D., Lahad, J., Jacob-Hirsch, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1987 · Cited by 488
Lacouture, M. E., Mitchell, E. P., Piperdi, B., Pillai, M. V., Shearer, H., Iannotti, N., Xu, F., & Yassine, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7828 · Cited by 478
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
The ADAMs: signalling scissors in the tumour microenvironment
Murphy, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2459 · Cited by 451
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Tonks, N. K. (2013) · The FEBS Journal · doi:10.1111/febs.12077 · Cited by 432
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Posttranscriptional regulation of cancer traits by HuR
Abdelmohsen, K., & Gorospe, M. (2010) · WIREs RNA · doi:10.1002/wrna.4 · Cited by 412
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
Inorganic Nanoparticles in Cancer Therapy
Bhattacharyya, S., Kudgus, R. A., Bhattacharya, R., & Mukherjee, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0318-0 · Cited by 395
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, C. R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J. S., Dutta, S., Muders, M., Wang, S., Buhrow, S. A., Safgren, S. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6102 · Cited by 371
Structure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367
Oncogenic EGFR Signaling Networks in Glioma
Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 363
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Koontongkaew, S. (2013) · Journal of Cancer · doi:10.7150/jca.5112 · Cited by 361
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
Bafna, S., Kaur, S., & Batra, S. K. (2010) · Oncogene · doi:10.1038/onc.2010.87 · Cited by 360
Development of Ewing's Sarcoma from Primary Bone Marrow–Derived Mesenchymal Progenitor Cells
Riggi, N., Cironi, L., Provero, P., Suvà, M.-L., Kaloulis, K., Garcia-Echeverria, C., Hoffmann, F., Trumpp, A., & Stamenkovic, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1696 · Cited by 359
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., & Kuriyan, J. (2007) · Nature · doi:10.1038/nature05998 · Cited by 357
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 343
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
The epidermal growth factor receptor: from development to tumorigenesis
Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00238.x · Cited by 340
Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Halverson, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3316 · Cited by 333
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Sawada, G., Niida, A., Uchi, R., Hirata, H., Shimamura, T., Suzuki, Y., Shiraishi, Y., Chiba, K., Imoto, S., Takahashi, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.035 · Cited by 332
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Mouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 331
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Heidarnejad maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 328
Feng, K., Liu, Y., Guo, Y., Qiu, J., Wu, Z., Dai, H., Yang, Q., Wang, Y., & Han, W. (2018) · Protein & Cell · doi:10.1007/s13238-017-0440-4 · Cited by 326
Rule-Based Modelling of Cellular Signalling
Danos, V., Feret, J., Fontana, W., Harmer, R., & Krivine, J. (2007) · Lecture Notes in Computer Science · doi:10.1007/978-3-540-74407-8_3 · Cited by 320
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Metadata
- Authors
- Hynes, N. E., & Lane, H. A.
- Venue
- Nature Reviews Cancer
- Published
- 2005-05-01
- Volume
- 5
- Issue
- 5
- Pages
- 341-354
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1974024530
- Cited by
- 3,313
- References
- 168
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.